Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

ABSTRACT:

Purpose of review

In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined.

Recent findings

Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free sur

SUBMITTER: Pham JP 

PROVIDER: S-EPMC10164011 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature